CTC count predicts survival in mBC
As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).
VPAC1 overexpression associated with colon cancer aggression
As reported in Tumor Biology, VPAC1 expression is increased in poorly differentiated compared to well-differentiated colon cancer. VPAC1 expression is also increased in the blood vessels and macrophages adjacent to colon cancer tissues compared to healthy tissues. The overexpression of VPAC1 is related to EGFR overexpression.
YKL-40 predicts poor prognosis for bladder cancer
As reported in Urologic Oncology, the gene expression and serum level of YKL-40 are higher in patients with bladder cancer than healthy controls. Serum YKL-40 levels predict poor prognosis in patients with muscle-invasive bladder cancer (HR=1.75).